Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Temple scientists receive $11.5 million grant for heart failure research

Innovative treatments for heart failure are lacking, leaving the nearly six million Americans who suffer from the condition with little hope for a cure. But thanks to an $11.5-million Program Project Grant (PPG) from the National Heart, Lung, and Blood Institute (NHLBI), scientists at Temple University School of Medicine are now set to further their investigation of key molecular mechanisms in heart failure, an effort that is expected to lead to the development of new heart therapies.

Abiomed receives Continuous Access Protocol (CAP) for RECOVER RIGHT Impella RP study

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced it has received approval for implementation of a Continuous Access Protocol (CAP) from the Food & Drug Administration (FDA) for RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella(R) RP (Right Peripheral) System.

SynCardia Total Artificial Heart with SynHall valves receives CE mark

On April 17, 2014, SynCardia Systems, Inc. received the CE Mark for the SynCardia temporary Total Artificial Heart with SynHall valves, providing the company with control over the last key component required for heart manufacturing.

Minneapolis Heart Institute Foundation announces its first implant of world's smallest cardiac pacemaker

The Minneapolis Heart Institute Foundation (MHIF) announced today the first implant of the world's smallest pacemaker at the Minneapolis Heart Institute. The device was implanted as part of a global clinical trial and the procedure was the first of its kind in the Midwest.

Thumbnail

Waiting, but not idle

A patient who is on a heart transplant waiting list became the first participant with a total artificial heart to complete the 4.2-mile course at the annual Pat’s Run event in Tucson, Ariz. AZ Central Channel i2 News reported on the accomplishment.

Celladon receives breakthrough therapy designation from FDA for MYDICAR(R), novel, first-in-class therapy in development to treat heart failure

Celladon Corporation, a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative.

Takeda presents additional data from the EXAMINE cardiovascular safety outcomes trial at the American College of Cardiology's 63rd annual scientific session

March 27, 2014—Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically investigated the effects of the dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin on rates of CV mortality and hospitalization for heart failure (HF).

Pitt study examines benefits of depression treatment for heart failure patients

Can treating depression in patients with heart failure help them live longer? That's one of the questions that University of Pittsburgh researchers hope to answer with a new five-year, $7.3 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH).

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup